Publication
Controlled Goods Data: Overview of the Regulatory Framework
The Controlled Goods Program (“CGP”) is Canada’s domestic industrial security program, which regulates the examination, possession, and transfer of controlled goods.
US OSHA wants better EHS programs in healthcare facilities
Author:
United States | Publication | February 18, 2022
On February 17, 2022, federal OSHA announced its initiative urging healthcare and related industries to take immediate actions to help make 2022 safer for their employees. OSHA noted an almost 250 percent increase in injury and illness incidence rates among healthcare and social assistance workers commencing in 2020, largely attributed to the COVID pandemic, and leading to combined totals greater than any other American industry.
To that end, OSHA continues to work on its final standard to protect healthcare workers from COVID. In the interim, OSHA emphasizes that employers must continue to comply with their obligations under the General Duty Clause, and the Personal Protective Equipment, Respiratory Protection and other relevant standards to protect employees from COVID hazards in the workplace.
Moreover, OSHA states that employers should create and implement proactive safety and health programs that address recognized hazards, training and preventive measures to keep workers safe. Companies are encouraged to utilize local OSHA On-Site Consultation personnel (1-800-321-OSHA (6742) and OSHA's program website) to discuss program development and conduct on-site safety and health evaluations.
Chief Integration Partner, Life Sciences and Healthcare, United States
Email
yvonne.puig@nortonrosefulbright.com
Recent publications
Publication
Government of Alberta launches nuclear energy engagement
On August 25, 2025, the Government of Alberta publicly re-affirmed its interest in nuclear energy with the launch of its Nuclear Energy Engagement (the Engagement).
Publication
Health Canada’s proposal to streamline approvals may accelerate biosimilar patent litigation
Health Canada has proposed a major change to the regulation of biosimilar drugs that may accelerate biologic patent litigation in Canada. Following the lead of other jurisdictions, Health Canada has proposed that biosimilar manufacturers no longer be required to conduct phase 3 clinical trials to enter the Canadian market.
Subscribe and stay up to date with the latest legal news, information and events . . .